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Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK),MET, and ROS1, is approved for treatment
of patients with ALK-positive or ROS1-positive advanced non-small-cell lung cancer (NSCLC). How-
ever, ALK rearrangements are also implicated in other malignancies, including anaplastic large-cell
lymphoma and inflammatory myofibroblastic tumors (IMTs). In this ongoing, multicenter, single-arm,
open-label phase 1b study (PROFILE 1013; NCT01121588), patients with ALK-positive advanced
malignancies other than NSCLC were to receive a starting dose of crizotinib 250 mg twice daily. Pri-
mary endpoints were safety and objective responses based on Response Evaluation Criteria in Solid
Tumors version 1.1 or National Cancer Institute International Response Criteria. Forty-four patients
were enrolled (lymphoma, n518; IMT, n59; other tumors, n517). The objective response rate was
53% (95% confidence interval [CI], 28–77) for lymphoma, with 8 complete responses (CRs) and 1 par-
tial response (PR); 67% (95% CI, 30–93) for IMTs, with 1 CR and 5 PRs; and 12% (95% CI, 2–36) for
other tumors, with 2 PRs in patients affected by colon carcinoma andmedullary thyroid cancer, respec-
tively. The median duration of treatment was almost 3 years for patients with lymphoma and IMTs,
with 2-year progression-free survival of 63% and 67%, respectively. The most common treatment-
related adverse events were diarrhea (45.5%) and vision disorders (45.5%), mostly grade 1. These find-
ings indicate strong and durable activity of crizotinib in ALK-positive lymphomas and IMTs. The safety
profilewas consistentwith the known safety profile of crizotinib evenwith long-term treatment.
*Carlo Gambacorti-Passerini and Tae Min Kim contributed equally to the lead
authorship of this article.
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Activating mutations or translocations of the anaplastic lymphoma
kinase (ALK) oncogene have been recurrently identified in several can-
cer types, including non-small-cell lung cancer (NSCLC), anaplastic
large-cell lymphoma (ALCL), inflammatory myofibroblastic tumors
(IMTs), and neuroblastoma.1–3 Activation of the ALK gene usually
occurs through chromosomal rearrangement, resulting in the placement
of one of several different 5ʹ fusion partners and their associated pro-
moter regions upstream of the ALK kinase domain. ALK point muta-
tions and possibly overexpression of ALK can also lead to activation of
ALK signaling in human tumors.4–6
ALCL is a rare form of non-Hodgkin lymphoma (NHL), usually con-
sisting of large neoplastic cells with abundant cytoplasm and pleomorphic
nuclei, with a translocation involving the ALK gene, and expression of
ALK protein and CD30. It accounts for 3% of adult and 10%–15% of
pediatric NHL cases.7–9 ALCL may be effectively treated using intensive
chemotherapy regimens (e.g. cyclophosphamide, doxorubicin, vincristine,
and prednisone [CHOP])10,11 but at the cost of early and long-term toxic-
ities.8,12 In addition, if relapse occurs after first-line treatment, ALCL has
a poor prognosis and tends to follow a very aggressive clinical course.13
IMTs are a rare type of mesenchymal neoplasm composed of a
variable mixture of myofibroblasts and inflammatory infiltrates that can
occur throughout the body, predominantly in the mesentery, retroperi-
toneum, and pelvis. ALK rearrangements have been implicated in giving
rise to oncogenic fusion proteins in 50% of IMTs.14–18 In addition,
activating ALK mutations are found in about 7%–9% of cases of neuro-
blastoma, a childhood cancer of the developing nervous system.19,20
Single-agent clinical protocols facilitate rapid enrollment of molec-
ularly profiled patients with genetic alterations linked to targeted thera-
pies, and early signs of clinical activity in such trials provide
opportunities for detection of new indications using a patient-sparing
design that could lead to subsequent confirmatory trials.21
Crizotinib is a potent, orally administered, small-molecule tyrosine
kinase inhibitor of ALK, MET, and ROS1 receptor tyrosine kinases.22,23
Currently, crizotinib has received marketing authorization approvals
globally for the treatment of ALK-positive advanced NSCLC in over 90
countries. In 2016, crizotinib was also approved in the United States
and European Union for the treatment of patients with advanced
NSCLC whose tumors are ROS1-positive.24
Here, we report the results of the PROFILE 1013 study that eval-
uated the safety and antitumor activity of single-agent, oral crizotinib
among patients with advanced ALCL, IMT, or other advanced ALK-
positive malignancies different from NSCLC.
2 | METHODS
2.1 | Patients
Patients aged15 years with Eastern Cooperative Oncology Group per-
formance status of 0–3 and histologically or cytologically proven diagno-
sis of ALCL, IMT, or other advanced malignancy (excluding NSCLC) for
which no standard therapy is available were eligible if they were positive
during local ALK testingwith validatedmethods at study sites for either:
 ALK gene translocation or inversion events (e.g., nucleophosmin
[NPM]-ALK fusion) as determined by fluorescence in situ hybridiza-
tion (FISH), reverse transcriptase (RT)–polymerase chain reaction
(PCR) or sequencing, or immunohistochemistry (in the case of ALCL)
 ALK-activating point mutations determined by direct sequencing of
the ALK gene locus
 ALK amplification events (defined as ALK/CEP2 ratio of 5 in 15%
of evaluated cells by FISH or as >7 copies by quantitative PCR or
array comparative genomic hybridization).
Local ALK testing results were reviewed by the Sponsor to confirm eli-
gibility. Solid tumors had to be measurable per Response Evaluation
Criteria in Solid Tumors (RECIST) version 1.1 and lymphomas had to be
measurable per the National Cancer Institute (NCI) International
Response Criteria for NHL. Patients with mutations or amplifications
involving c-MET, who were receiving concurrent treatment on another
clinical trial, or who had received prior therapy specifically directed
against ALK, were excluded.
2.2 | Trial design and treatment
This ongoing, multicenter, open-label, single-arm exploratory phase 1b
study (PROFILE 1013; ClinicalTrials.gov identifier: NCT01121588)25
enrolled patients with advanced malignancies (NHL, IMT, and solid
tumors) harboring a translocation, inversion, mutation, or amplification
event involving the ALK gene locus. Crizotinib, at a starting dose of
250mg twice daily, was to be orally administered on a continuous dosing
schedule in 21-day cycles to facilitate scheduling of visits and assess-
ments. Patients were permitted to continue treatment with crizotinib if
there was evidence of clinical benefit in the opinion of the investigators.
2.3 | Trial assessments
Patientswere to be screened before receiving crizotinib. Subsequent vis-
its were to be scheduled for days 1 and 15 of cycle 1 and then day 1 of all
following treatment cycles, with a final visit at the end of treatment. After
a protocol amendment (August 2015), a reduced visit frequency sched-
ule (visits on day 1 of every 6 cycles) was to be followed for ongoing
patients. Assessments of adverse events (AEs), laboratory safety (hema-
tology, chemistry, and coagulation [cycle 1 only]), physical examinations,
and electrocardiograms (cycles 1 and 2 only) were to be performed at
each visit. Safety assessments included collection of AEs, serious AEs
(SAEs), vital signs, physical examinations, 12-lead electrocardiograms,
laboratory assessments (including pregnancy tests), ophthalmologic
examinations, and documentation of concomitant treatments. On-study
tumor assessmentswere to be performed at the beginning of cycle 3 and
every other cycle up to and including cycle 10. After cycle 10, tumor
assessments were to be performed every 12weeks, reduced to every 24
weeks from cycle 26 and to every 52 weeks from cycle 52. Tumor
assessments were reviewed by the investigators at study sites.
2.4 | Endpoints
The primary endpoints were objective response rate (ORR) based on
RECIST v1.1 or the NCI International Response Criteria, the type,
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incidence, severity, seriousness, and relationship to study medications
of AEs, and laboratory abnormalities. Secondary endpoints included
progression-free survival (PFS), overall survival (OS) at 6 months and 1
and 2 years, OS, and duration of response (DOR).
2.5 | Trial oversight
PROFILE 1013 was designed by Pfizer and conducted in collaboration
with the principal investigators (see Supporting Information). All
patients provided written informed consent before enrollment. The
institutional review board or independent ethics committee at each
participating center approved the protocol and amendments, which
complied with the International Ethical Guidelines for Biomedical
Research Involving Human Subjects, Good Clinical Practice guidelines,
the Declaration of Helsinki, and local laws.
2.6 | Statistical analysis
The sample size for this study was determined empirically based on
expected small numbers of patients in the population of interest, and it
was anticipated that approximately 40 patients would be enrolled. The
study population for all analyses (except tumor response-related end-
points) included patients enrolled in the study who received at least
one dose of crizotinib. For response-related endpoints, enrolled
patients who received at least one dose of crizotinib also had to have
an adequate baseline tumor assessment.
Descriptive statistics were used to summarize patient characteris-
tics, treatment administration, antitumor activity, and safety. The ORR
was summarized with the corresponding exact 2-sided 95% confidence
interval (CI) calculated using a method based on the F distribution. Sec-
ondary time-to-event endpoints were summarized using Kaplan-Meier
methods. The data cutoff date was March 4, 2016. Data were summar-
ized for the overall patient population, as well as separately for antitu-
mor activity in the ALCL, IMT, and “other tumors” patient groups.
3 | RESULTS
3.1 | Patients
From March 2011 through October 2013, a total of 44 patients were
enrolled in the study (lymphoma, n518; IMT, n59; and other tumors,
n517). Demographic characteristics are shown in Table 1, and
patients’ diagnoses in the other tumors group are shown in Supporting
Information Table S1. All enrolled patients were either white or Asian
in nearly equal proportions (Japanese, Korean, or Chinese).
3.2 | Antitumor activity
3.2.1 | Lymphoma group
In the lymphoma group, 17 of 18 patients were evaluable for response
(Table 2), as 1 patient was retrospectively found not to have measura-
ble disease. The patient was followed for antitumor activity based on
positive RT-PCR status for NPM-ALK, which predicts a poor progno-
sis,26 and became RT-PCR negative within 4 months of treatment; this
patient was still on treatment and relapse-free at the data cutoff (at
cycle 74), after more than 4 years on crizotinib. Patients in the lym-
phoma group had an ORR of 52.9% (95% CI, 27.8–77.0). This com-
prised 8 patients (47.1%) who experienced a complete response (CR)
and 1 patient (5.9%) with a partial response (PR). Median DOR was 2.6
years with all but 1 patient still in response or ongoing at the time of
data cutoff (Supporting Information Figure S1). In addition, 3 patients
(17.6%) had stable disease (SD), including one lasting over 3.5 years
and ongoing at data cutoff in a patient with diffuse large B-cell lym-
phoma (DLBCL). Median PFS had not been reached (Figure 1) because
of the small number of events (33%) and the high percentage of
patients with lymphoma still in follow-up for progression (44.4%). PFS
at 2 years was 63.0% (95% CI, 35.3–81.4). Of note, all responding
patients who progressed/relapsed did so within the initial 90 days of
treatment and no further progressions/relapses were noted thereafter.
Median OS was also not reached as OS data were immature, with
72.2% of patients with lymphoma still alive at the cutoff (Figure 2).
One patient underwent a cord stem cell transplant approximately
4 months after starting crizotinib treatment and was subsequently cen-
sored for evaluation of tumor response-related endpoints. The patient
resumed crizotinib after the transplant and was still ongoing and
disease-free at the data cutoff, after more than 4 years on crizotinib.
3.2.2 | IMT group
All patients with IMT were evaluable for response (Table 2). Patients in
the IMT group had an ORR of 66.7% (95% CI, 29.9–92.5), which com-
prised 1 CR and 5 PRs. Three patients are still in response, with
responses lasting over 2 years, and these patients remain in follow-up
(Supporting Information Figure S1). In addition, 3 patients (33.3%) had
SD. Median PFS was not reached in the IMT group (Figure 1) because
of the small number of events (33%) and 55.6% of patients with IMT
who remain in follow-up for progression. PFS at 2 years was 66.7%
(95% CI, 28.2–87.8). In addition, median OS was not reached as 66.7%
of patients with IMT were alive at the data cutoff (Figure 2).
3.2.3 | “Other tumors” group
All patients in the “other tumors” group were evaluable for response
(Table 2), and the ORR was 11.8% (95% CI, 1.5–36.4). This comprised
2 of 17 patients (11.8%) ALK-positive for rearrangement on FISH who
achieved a PR (one with mucinous carcinoma of the colon [response
duration, 103.3 weeks] and one with medullary thyroid cancer
[response duration, 16.1 weeks]). In addition, 4 patients (23.5%) had
SD, of which 1 patient with advanced neuroblastoma harboring ALK
F1174L mutation had SD lasting 19 months. Among patients with
other tumors, median PFS was 1.3 months (95% CI, 1.1–3.9) (Figure 1),
PFS at 2 years was 6.3% (95% CI, 0.4–24.7), and median OS was
8.3 months (95% CI, 2.2–16.9) (Figure 2).
3.3 | Safety
At the time of data cutoff, the duration of crizotinib treatment ranged
from 0.1 to 249.3 weeks (57 months) across all patients, with median
treatment durations of 35 months, 33 months, and 1 month for the
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lymphoma, IMT, and “other tumors groups”, respectively; a total of 16
of 44 patients (36.4%) were still receiving crizotinib treatment. At least
one AE of any cause was reported in 43 of 44 patients (97.7%)
(Supporting Information Table S2), and treatment-related AEs (TRAEs)
occurred in a total of 39 patients (88.6%) (Table 3). Mild-to-moderate
diarrhea and vision disorder were the most common TRAEs reported
(both 45.5%), most of which were grade 1.
Overall, 9 patients (20.5%) experienced an SAE considered to be
related to crizotinib treatment (Table 3). The most common SAE con-
sidered possibly related to treatment was grade 4 blood creatine phos-
phokinase increase reported in 3 patients (6.8%), all in clinical response
and concurrent with strenuous physical activity that is known to cause
brisk elevations of creatine phosphokinase levels.27
Grade 5 AEs considered by the investigator as related to treatment
occurred in 2 patients: cerebral infarction in a patient with unknown
primary tumor and multiple brain metastases, concurrent with disease
progression, and interstitial lung disease in a patient with nasopharyn-
geal carcinoma. Subsequent review by an independent radiology com-
mittee, consisting of a pulmonologist, radiologist, and oncologist,
indicated that this event was aspiration pneumonia and not related to
the study drug.
Permanent discontinuation of crizotinib associated with TRAEs
occurred in the 2 patients with cerebral infarction (2.3%) and interstitial
lung disease (2.3%). Disease progression led to permanent discontinua-
tion from treatment in 50% of patients.
Overall, 21 patients died during the study. Seventeen patients died
because of disease progression, 1 patient died from interstitial lung dis-
ease/aspiration pneumonia, and 1 patient died because of cerebral infarc-
tion (the latter 2 as previously described). During long-term follow-up, 1
patient died because of small bowel obstruction and hernia complication
(13months after treatment discontinuation) and 1 patient’s cause of death
(10months after treatment discontinuation) remained unknown.
4 | DISCUSSION
Crizotinib has been shown to be superior to standard chemotherapy in
previously treated and untreated patients with ALK-positive advanced
NSCLC28,29 and has previously been shown to have therapeutic activity










Male 12 (66.7) 5 (55.6) 8 (47.1) 25 (56.8)
Age, years
Median 25.0 32.0 53.0 32.0
Range 15–37 16–73 26–73 15–73
ECOG performance status
0 4 (22.2) 4 (44.4) 5 (29.4) 13 (29.5)
1 7 (38.9) 4 (44.4) 9 (52.9) 20 (45.5)
2 5 (27.8) 1 (11.1) 2 (11.8) 8 (18.2)
3 2 (11.1) 0 (0.0) 1 (5.9) 3 (6.8)
Race
White 12 (66.7) 4 (44.4) 7 (41.2) 23 (52.3)
Asian 6 (33.3) 5 (55.6) 10 (58.8) 21 (47.7)
Japanese 2 (11.1) 1 (11.1) 2 (11.8) 5 (11.4)
Korean 2 (11.1) 1 (11.1) 4 (23.5) 7 (15.9)
Chinese 2 (11.1) 3 (33.3) 4 (23.5) 9 (20.5)
Smoking classification
Never 10 (55.6) 6 (66.7) 14 (82.4) 30 (68.2)
Former 5 (27.8) 3 (33.3) 2 (11.8) 10 (22.7)
Current 3 (16.7) 0 (0.0) 1 (5.9) 4 (9.1)
Prior systemic therapy
No 0 (0.0) 6 (66.7) 1 (5.9) 7 (15.9)
Yes 18 (100) 3 (33.3) 16 (94.1) 37 (84.1)
No. of regimens
1 2 (11.1) 2 (22.2) 3 (17.6) 7 (15.9)
2 6 (33.3) 1 (11.1) 4 (23.5) 11 (25.0)
3 5 (27.8) 0 (0.0) 3 (17.6) 8 (18.2)
4 3 (16.7) 0 (0.0) 3 (17.6) 6 (13.6)
5 1 (5.6) 0 (0.0) 0 (0.0) 1 (2.3)
6 1 (5.6) 0 (0.0) 2 (11.8) 3 (6.8)
7 0 (0.0) 0 (0.0) 1 (5.9) 1 (2.3)
Data are presented as n (%) unless otherwise noted.
ECOG, Eastern Cooperative Oncology Group; IMT, inflammatory myofibroblastic tumor.
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in relapsed and resistant ALK-positive lymphomas.30–34 These findings,
together with previous studies, encourage the use of crizotinib as a
potential treatment option in ALK-positive lymphoma, although some
lack long-term follow-up data.
Patients with relapsed ALK-positive lymphoma generally have a poor
prognosis and, presently, there is no consensus on the optimal chemother-
apy combination for relapsedALCL.7,8 Brentuximab vedotin inducedobjec-
tive responses in a majority (86%) of 58 patients (57% CR, 29% PR) with
recurrent systemic ALCL (median DOR and PFS of 12.6 and 13.3 months,
respectively)35 and has been approved for the treatment of systemic ALCL
after failure of 1 prior multiagent chemotherapy regimen. However,
brentuximab vedotin is unlikely to represent a long-term treatment for
advanced ALCL because of its side effects (incremental neurotoxicity), par-
enteral route of administration, and general use as a bridge therapy.
Our study cohorts show notable and durable antitumor activity of
crizotinib as monotherapy for patients with advanced, relapsed or
refractory ALK-positive ALCL and ALK-positive IMT, together with a
FIGURE 2 Overall survival.
IMT, inflammatory myofibroblastic tumor
TABLE 3 Treatment-related AEs and SAEs in patients treated with
crizotinib (N544)
Maximum CTCAE
Event, n (%) Any grade Grade 3 Grade 4 Grade 5
Any AEa 39 (88.6) 16 (36.4) 6 (13.6) 2 (4.5)
AEs in 10% of patients
Diarrhea 20 (45.5) 0 (0.0) 0 (0.0) 0 (0.0)
Vision disorderb 20 (45.5) 0 (0.0) 0 (0.0) 0 (0.0)
Nausea 17 (38.6) 2 (4.5) 0 (0.0) 0 (0.0)
Elevated transaminasesb 15 (34.1) 3 (6.8) 0 (0.0) 0 (0.0)
Vomiting 15 (34.1) 3 (6.8) 0 (0.0) 0 (0.0)
Neutropeniab 14 (31.8) 8 (18.2) 2 (4.5) 0 (0.0)
Edemab 11 (25.0) 0 (0.0) 0 (0.0) 0 (0.0)
Abdominal painb 10 (22.7) 1 (2.3) 0 (0.0) 0 (0.0)
Leukopeniab 9 (20.5) 1 (2.3) 0 (0.0) 0 (0.0)
Fatigue 7 (15.9) 2 (4.5) 0 (0.0) 0 (0.0)
Headache 7 (15.9) 0 (0.0) 0 (0.0) 0 (0.0)
Constipation 6 (13.6) 0 (0.0) 0 (0.0) 0 (0.0)
CPK increased 5 (11.4) 1 (2.3) 3 (6.8) 0 (0.0)
Maximum CTCAE
Any grade Grade 3 Grade 4 Grade 5
Any SAEa 9 (20.5) 1 (2.3) 4 (9.1) 2 (4.5)
CPK increased 3 (6.8) 0 (0.0) 3 (6.8) 0 (0.0)
Cardiac failureb 1 (2.3) 0 (0.0) 1 (2.3)c 0 (0.0)
Cerebral infarction 1 (2.3) 0 (0.0) 0 (0.0) 1 (2.3)
Deep vein thrombosis 1 (2.3) 1 (2.3)c 0 (0.0) 0 (0.0)
Interstitial lung diseaseb 1 (2.3) 0 (0.0) 0 (0.0) 1 (2.3)
Myocardial ischemia 1 (2.3) 1 (2.3)c 0 (0.0) 0 (0.0)
aPatients are counted once under the highest CTCAE grade.
bThis item comprised a cluster of AEs that may represent similar clinical
symptoms or syndromes, listed in Supporting Information Table S3.
cDeep vein thrombosis (grade 3; n51)was concurrentwith a course of corti-
costeroids; myocardial ischemia (grade 3) and cardiac failure (grade 4) occurred
in the same patient, who had preexisting hypertension and coronary artery dis-
ease. These grade3 SAEswere considered possibly treatment-related by the
investigator; however, their relationship to concomitantmedications, coexist-
ingmedical conditions, or tumor progression could not be clearly established.
AE, adverse event; CPK, creatine phosphokinase; CTCAE, Common Ter-
minology Criteria for Adverse Events; SAE, serious adverse event.







Best overall response, n (%)
Complete response 8 (47.1) 1 (11.1) 0 (0.0)
Partial response 1 (5.9) 5 (55.6) 2 (11.8)
Stable disease 3 (17.6) 3 (33.3) 4 (23.5)
Objective progression 3 (17.6) 0 (0.0) 7 (41.2)
Early death 1 (5.9) 0 (0.0) 3 (17.6)
Indeterminate 1 (5.9) 0 (0.0) 1 (5.9)
Objective response rate, % 52.9 66.7 11.8
95% CI 27.8–77.0 29.9–92.5 1.5–36.4
Duration of response, weeks
Median 135.9 74.1 59.7
Range 6.0–205.9 29.6–138.3 16.1–103.3
Stable disease duration, n (%)a
<3 months 2 (66.7) 0 (0.0) 0 (0.0)
3–<6 months 0 (0.0) 1 (33.3) 2 (50.0)
6–<9 months 0 (0.0) 0 (0.0) 1 (25.0)
9–<12 months 0 (0.0) 0 (0.0) 0 (0.0)
12 months 1 (33.3) 2 (66.7) 1 (25.0)
aPercentages based on the number of patients with stable disease.
CI, confidence interval; IMT, inflammatory myofibroblastic tumor.
FIGURE 1 Progression-free survival.
IMT, inflammatorymyofibroblastic tumor
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favorable safety profile that was consistent over long-term treatment.
This study suggests that crizotinib may also offer a potential long-term
treatment option, with an OS at 2 years similar to that reported with
first-line CHOP chemotherapy in patients with ALK-positive ALCL36
and a PFS at 2 years that exceeds 60% in ALK-positive ALCL. Abrupt
relapses of ALK-positive lymphoma following crizotinib discontinuation
have been reported, and it has been suggested that caution must be
exercised when interrupting treatment in patients with ALK-positive
lymphomas, since ALCL may recur rapidly.32
One patient in this study had ALK-positive DLBCL and experi-
enced SD lasting almost 4 years, a clinically meaningful response for
this rare form of lymphoma that exhibits a more aggressive clinical
course and worse prognosis than typical DLBCL.37
Sustained and durable responses to crizotinib in lymphoma were
observed in another study performed in 26 pediatric patients with
relapsed or refractory ALK-positive ALCL, which represent an update of
a previous publication.33 Although a high response rate of 90% was
observed in the Children’s Oncology Group study, one-half of patients
ultimately received stem cell transplantation,34 thus rendering the evalu-
ation of the long-term effects of crizotinib in this population problematic.
In PROFILE 1013, this was not a confounding factor as only 1 responder
underwent bonemarrow transplantation andwas censored at that time.
Previous reports have shown that crizotinib has antitumor activity in
patients with unresectable ALK-positive IMTs34 as well as in those with
refractory ALK-positive IMT.33,38 A case report of a patient with ALK-
positive IMT documented complete radiographic remission 2 years after
initiating crizotinib treatment.39 The results of our study indicate a
marked antitumor activity, with nearly two-thirds of objective responses
lasting >2 years and a PFS at 2 years of 67%. The durable responses
observed in this small set of patients further support the National Com-
prehensive Cancer Network’s recommendation of crizotinib as a treat-
ment for IMTs with an ALK rearrangement40 and suggest that ALK
testing should be routinely performed in all patients with IMT.
In contrast, a low level of response was observed in the “other
tumors” group, which included a variety of ALK-positive tumors. Poten-
tial reasons for lack of clinical activity include differences in ALK signal-
ing events in different tumor types (i.e., “early” vs “late” events during
tumor progression), differing tumor types, and genetics of the tumor
cell, which may affect the response to ALK tyrosine kinase inhibitors.41
In addition, point mutations permitted in this study, for example
F1174L and F1245C (common ALK-activating mutations seen in neuro-
blastoma), have been shown to confer resistance to crizotinib in neuro-
blastoma and other cancers.33,42,43 MYCN overexpression has also
been associated with resistance to ALK inhibitors.44 However, in this
subgroup, 1 patient with mucinous carcinoma of the colon achieved a
long-lasting response of almost 2 years, 1 patient with medullary thy-
roid carcinoma also responded to crizotinib with a response duration of
4 months, and 1 patient with neuroblastoma had SD for 19 months,
suggesting that ALK alterations may act as an oncogenic driver and can
potentially be targeted in other malignancies.
Previously, safety data were reported from studies of crizotinib
with median treatment durations of only 10.9 months,28 which is sub-
stantially less than the median treatment duration in the ALCL and IMT
groups in this study (35 and 33 months, respectively). The treatment
durations (up to 57 months) in this study are currently the longest
reported in the literature in adult patients and therefore provide new
information about the long-term safety of crizotinib.
Crizotinib was generally well tolerated; the safety profile observed
was similar to that reported previously with crizotinib, and no new
safety signals were identified.28,29,45 Limitations of this study include
its single-arm, open-label design, small patient population, and the het-
erogeneity of the patients’ tumors.
In conclusion, this study indicated strong and durable activity of
crizotinib in ALK-positive lymphomas and IMTs. Treatment duration
was much longer than usual treatment in patients with NSCLC, and the
safety profile was consistent with the known safety profile of crizoti-
nib, even with long-term treatment.
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